Medication info
Unisimva Tablet 5 mg (Simvastatin)

Unisimva Tablet 5 mg (Simvastatin)

Prescription medicationTabletOral
Ingredient · strength
Simvastatin›5mg / 1 tablet
Manufacturer / importer
Unimed Pharmaceuticals Co., Ltd.
Appearance
Light yellowish-brown round film-coated tablet
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201504313 · Approved 2015.06.30 · Insurance code 649506790

Summary

Main use
Treatment of hyperlipidemia and heterozygous familial hypercholesterolemia in children
Who takes it
Adults · Children
Adult dose
Patients must follow a standard cholesterol-lowering diet before and during treatment with this medicine. 1. Hyperlipidemia 1) Risk reduction in patients with coronary heart disease and hypercholesterolemia, and hyperlipidemia The usual recommended starting dose is 20 mg of this medicine once daily in the evening. Patients with mild to moderate hypercholesterolemia may start with 10 mg of this medicine. The recommended dose is 5 ~ 40 mg of this medicine once daily in the evening. Adjust the dose as appropriate according to the initial LDL-cholesterol level before starting treatment, the treatment target, and the patient's response to the medicine. Measure cholesterol levels 4 weeks after starting treatment and periodically thereafter, and adjust the dose. Reduce the dose if cholesterol levels fall below the target level. Because of the increased risk of myopathy, including rhabdomyolysis, use of the 80 mg dose of this medicine, particularly during the first year of treatment, is restricted to patients who have taken 80 mg of this medicine for 12 months or longer without evidence of muscle toxicity (see section 1. Warnings in Precautions for Use). 2) For recommended doses in patients receiving this medicine concomitantly with fibrates (excluding gemfibrozil and fenofibrate), amiodarone, verapamil, diltiazem, or amlodipine, and in certain patient groups (i.e., patients with homozygous familial hypercholesterolemia, elderly patients, and patients with renal impairment), refer to the information below. (1) Administration to patients with homozygous familial hypercholesterolemia In controlled clinical trials, patients with homozygous familial hypercholesterolemia received 40 mg of this medicine once daily in the evening. Administer this medicine in combination with other lipid-lowering therapy (e.g., LDL apheresis), or when other lipid-lowering therapy is not available. (2) In elderly patients, the maximum cholesterol-lowering effect may be achieved with a daily dose of 20 mg of this medicine. (3) Administration to patients receiving verapamil, diltiazem, or dronedarone When this medicine is coadministered to patients receiving verapamil, diltiazem, or dronedarone, the dose of this medicine should not exceed 10 mg daily. (4) Administration to patients receiving amiodarone, amlodipine, or ranolazine When this medicine is coadministered to patients receiving amiodarone, amlodipine, or ranolazine, the dose of this medicine should not exceed 20 mg daily (see section 6. Drug Interactions in Precautions for Use). (5) Concomitant administration with other lipid-lowering agents This medicine is effective when administered alone or in combination with a bile acid sequestrant. When this medicine is coadministered with a fibrate (excluding gemfibrozil (see section 2. Patients in Whom the Medicine Is Contraindicated in Precautions for Use) and fenofibrate), the dose of this medicine should not exceed 10 mg daily. (See section 6. Drug Interactions in Precautions for Use). (6) Administration to patients with renal impairment Since this medicine is not substantially excreted by the kidneys, dosage adjustment is not necessary in patients with mild to moderate renal impairment. However, in patients with severe renal impairment, start with an initial dose of 5 mg daily and monitor carefully.
Child dose
Pediatric patients with heterozygous familial hypercholesterolemia (10∼17 years of age): The recommended initial dose is 10 mg of this medicine once daily in the evening. The recommended dose range is 10 ~ 40 mg daily, and the recommended maximum dose is 40 mg daily. Adjust the dose individually according to the recommended treatment goal. Allow an interval of 4 weeks or longer between dose adjustments.

Ingredients

Manufacturer
Unimed Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of hyperlipidemia and heterozygous familial hypercholesterolemia in children

  • Hyperlipidemia
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
  • dys-beta-lipoproteinemia
  • hypertriglyceridemia
  • homozygous familial hypercholesterolemia
View approved original text

This drug is used for the treatment of hyperlipidemia, reducing total cholesterol and LDL-cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia, while also lowering Apo-B protein and triglyceride levels and increasing HDL-cholesterol levels. It is also helpful in the treatment of dys-beta-lipoproteinemia and hypertriglyceridemia. It is used particularly in cases of homozygous familial hypercholesterolemia when other treatments are inadequate or cannot be used. This drug is also used as an adjunctive therapy to reduce LDL-cholesterol and Apo-B protein levels in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia, in conjunction with dietary therapy. It is important to confirm the cause of secondary hyperlipidemia and measure lipid levels before starting treatment. This drug is effective for managing hyperlipidemia and improving cardiovascular disease risk.

How to take

Adult dose

Patients must follow a standard cholesterol-lowering diet before and during treatment with this medicine. 1. Hyperlipidemia 1) Risk reduction in patients with coronary heart disease and hypercholesterolemia, and hyperlipidemia The usual recommended starting dose is 20 mg of this medicine once daily in the evening. Patients with mild to moderate hypercholesterolemia may start with 10 mg of this medicine. The recommended dose is 5 ~ 40 mg of this medicine once daily in the evening. Adjust the dose as appropriate according to the initial LDL-cholesterol level before starting treatment, the treatment target, and the patient's response to the medicine. Measure cholesterol levels 4 weeks after starting treatment and periodically thereafter, and adjust the dose. Reduce the dose if cholesterol levels fall below the target level. Because of the increased risk of myopathy, including rhabdomyolysis, use of the 80 mg dose of this medicine, particularly during the first year of treatment, is restricted to patients who have taken 80 mg of this medicine for 12 months or longer without evidence of muscle toxicity (see section 1. Warnings in Precautions for Use). 2) For recommended doses in patients receiving this medicine concomitantly with fibrates (excluding gemfibrozil and fenofibrate), amiodarone, verapamil, diltiazem, or amlodipine, and in certain patient groups (i.e., patients with homozygous familial hypercholesterolemia, elderly patients, and patients with renal impairment), refer to the information below. (1) Administration to patients with homozygous familial hypercholesterolemia In controlled clinical trials, patients with homozygous familial hypercholesterolemia received 40 mg of this medicine once daily in the evening. Administer this medicine in combination with other lipid-lowering therapy (e.g., LDL apheresis), or when other lipid-lowering therapy is not available. (2) In elderly patients, the maximum cholesterol-lowering effect may be achieved with a daily dose of 20 mg of this medicine. (3) Administration to patients receiving verapamil, diltiazem, or dronedarone When this medicine is coadministered to patients receiving verapamil, diltiazem, or dronedarone, the dose of this medicine should not exceed 10 mg daily. (4) Administration to patients receiving amiodarone, amlodipine, or ranolazine When this medicine is coadministered to patients receiving amiodarone, amlodipine, or ranolazine, the dose of this medicine should not exceed 20 mg daily (see section 6. Drug Interactions in Precautions for Use). (5) Concomitant administration with other lipid-lowering agents This medicine is effective when administered alone or in combination with a bile acid sequestrant. When this medicine is coadministered with a fibrate (excluding gemfibrozil (see section 2. Patients in Whom the Medicine Is Contraindicated in Precautions for Use) and fenofibrate), the dose of this medicine should not exceed 10 mg daily. (See section 6. Drug Interactions in Precautions for Use). (6) Administration to patients with renal impairment Since this medicine is not substantially excreted by the kidneys, dosage adjustment is not necessary in patients with mild to moderate renal impairment. However, in patients with severe renal impairment, start with an initial dose of 5 mg daily and monitor carefully.

Child dose

Pediatric patients with heterozygous familial hypercholesterolemia (10∼17 years of age): The recommended initial dose is 10 mg of this medicine once daily in the evening. The recommended dose range is 10 ~ 40 mg daily, and the recommended maximum dose is 40 mg daily. Adjust the dose individually according to the recommended treatment goal. Allow an interval of 4 weeks or longer between dose adjustments.

Precautions

This drug may have side effects affecting the muscles, so if muscle pain or weakness occurs, especially when taking high doses, consult a doctor immediately. This drug may affect liver function, so it should be avoided in patients with liver disease or elevated liver enzyme levels, and periodic liver function tests are important. Women who are pregnant or may become pregnant, as well as breastfeeding women, should not take this drug, and those planning to become pregnant should consult a doctor. When used in combination with certain medications, there may be an increased risk of muscle damage, so patients taking other drugs should inform their healthcare provider. Elderly patients, those with impaired kidney function, and patients with hypothyroidism need to use this drug with caution and should follow their doctor's instructions. This drug contains lactose, so patients with lactose intolerance should not take it. If unexplained muscle pain, tenderness, or weakness occurs while taking this drug, stop taking it immediately and consult a healthcare provider. Some patients may experience side effects such as dyspepsia, headache, constipation, diarrhea, so if symptoms are severe, consult a doctor. Avoid taking grapefruit juice or certain drugs while on this medication, as this may increase the drug's blood concentration and the risk of side effects. This drug can raise blood sugar levels, so patients at risk for diabetes should periodically check their blood sugar. When receiving prescriptions for new medications during treatment, inform your healthcare provider about this drug you are taking. This drug is not for use in children or patients under 10 years of age; pediatric patients should follow a doctor's instructions for use. Store this medication out of reach of children and keep it in its original container.

Side effects

Myopathy, rhabdomyolysis, abdominal pain, weakness, constipation, diarrhea, dyspepsia, bloating, nausea, headache, upper respiratory infection, edema, atrial fibrillation, gastritis, diabetes mellitus, myalgia, insomnia, dizziness, bronchitis, sinusitis, eczema, urinary tract infection, muscle cramps, arthralgia, dysgeusia, ocular movement disorders, facial paresis, tremor, sensory disturbances, peripheral neuropathy, peripheral nerve paralysis, mental disorders, anxiety, sleep disorders, nightmares, depression, cognitive impairment, anaphylaxis, angioedema, lupus-like erythematosus syndrome, polymyositis, dermatomyositis, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive antinuclear antibody, increased erythrocyte sedimentation rate, eosinophilia, arthritis, urticaria, photosensitivity, fever, chill, flushing, malaise, dyspnea, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, pancreatitis, hepatitis, liver failure, cholestatic jaundice, hepatic steatosis, cirrhosis, fulminant hepatic necrosis, liver cancer, loss of appetite, vomiting, alopecia, pruritus, skin changes, gynecomastia, decreased libido, sexual dysfunction, progression of cataract, ocular muscle paralysis, anemia, elevated aminotransferases, elevated ALP, elevated γ-GTP, increased bilirubin levels, thyroid dysfunction, elevated serum creatine kinase, abnormal liver function tests, limb sensory impairment, paresthesia, cold sensation, muscle weakness, thrombocytopenia, interstitial lung disease, optic nerve degeneration, vestibular cochlear degeneration, retinal ganglion cell chromatin dissolution, perivascular hemorrhage, perivascular edema, perivascular monocyte infiltration, perivascular fibrin deposition, microvascular necrosis, hepatitis, jaundice, liver dysfunction, muscle weakness, myalgia, muscle tenderness, elevated creatine kinase, proximal muscle weakness, memory decline, forgetfulness, amnesia, memory impairment, confusion, vomiting, mucous stools

Not everyone experiences these, and they can vary from person to person.

Storage

This drug may be sensitive to air and moisture, so it should be stored in a closed container. Additionally, it is best to store this medication at room temperature between 1°C and 30°C. This will help maintain the medication's effect and ensure safe use.

Appearance and packaging

Appearance

Light yellowish-brown round film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.